Abstract
Second generation ALK-inhibitors have shown improvement in brain disease control compared with Crizotinib in patients with metastatic ALK+ NSCLC. However, Crizotinib is the only treatment covered by the Brazilian private health care system (BHCS) so far. The objective of this study was to evaluate the cost-effectiveness of first-line Brigatinib in patients with ALK+ NSCLC and brain metastases at diagnosis, in comparison with Crizotinib and Alectinib, according to BHCS perspective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
